Skip to content

Clinical trials

Phase 1 Endometrial Neoplasms trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Endometrial Neoplasms Phase: Phase 1 Clear all

229 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20015
20021
20032
20045
20052
20062
20073
20085
20093
20107
201110
20123
20132
20147
20157
20167
20179
20187
201916
202011
202114
202214
202318
202422
202520
202618

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed85
Recruiting54
Terminated32
Active, not recruiting27
Unknown status12
Not yet recruiting8
Withdrawn8
Suspended2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)13
M.D. Anderson Cancer Center7
UNC Lineberger Comprehensive Cancer Center6
Eli Lilly and Company5
Memorial Sloan Kettering Cancer Center5
Washington University School of Medicine5
Xencor, Inc.4
Dana-Farber Cancer Institute3
GlaxoSmithKline3
Mayo Clinic3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Endometrial Neoplasms229
Ovarian Neoplasms111
Breast Neoplasms74
Uterine Cervical Neoplasms70
Carcinoma, Non-Small-Cell Lung69
Stomach Neoplasms57
Colorectal Neoplasms44
Triple Negative Breast Neoplasms44
Neoplasms41
Fallopian Tube Neoplasms40

Trials

Showing 1 to 25 of 229. Each trial links to its page on Pharma Observatory.

129 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.